Clinical Trials for Stroke
532 stroke trials indexed, 236 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Stroke
Stroke occurs when blood flow to a part of the brain is interrupted or reduced, preventing brain tissue from getting oxygen and nutrients. This can happen due to a blocked artery (ischemic stroke) or bleeding in the brain (hemorrhagic stroke). The underlying biology involves damage to brain cells caused by lack of oxygen or pressure from bleeding. Doctors diagnose stroke using a combination of physical exams, patient history, and imaging tests like CT scans or MRIs to identify the type and location of the stroke.
Common symptoms of stroke include sudden weakness or numbness on one side of the body, difficulty speaking or understanding speech, vision problems, dizziness, and severe headache. Stroke often affects people over the age of 65, but it can occur at any age. Those with high blood pressure, diabetes, smoking habits, or a family history of stroke are at higher risk. Certain conditions like atrial fibrillation or high cholesterol also increase the chance of having a stroke.
Stroke is a major cause of death and disability worldwide. In the United States alone, about 795,000 people experience a stroke each year. It is the fifth leading cause of death and a leading cause of serious long-term disability. The economic burden is significant, with costs related to healthcare and lost productivity reaching billions annually. Early diagnosis and treatment are critical to reduce the damage and improve recovery outcomes.
The Stroke Treatment Landscape
The first-line treatment for ischemic stroke typically involves restoring blood flow as quickly as possible. This often starts with clot-busting drugs, known as thrombolytics, such as tissue plasminogen activator (tPA). These drugs are most effective when given within a few hours of symptom onset. In some cases, mechanical thrombectomy is performed, where doctors physically remove the clot using specialized devices. Immediate care also includes stabilizing vital signs and preventing complications.
When first-line treatments are not suitable or effective, doctors may consider second-line options. These include anticoagulants and antiplatelet drugs that help prevent new clots from forming. Examples include aspirin and warfarin, which are commonly used to reduce the risk of recurrent stroke. In some cases, managing underlying conditions like atrial fibrillation with medications is essential. Third-line treatments may involve rehabilitation therapies such as physical, occupational, and speech therapy to help patients regain lost functions.
Despite available treatments, many patients do not fully recover or face serious side effects. Some subgroups, such as those with hemorrhagic stroke or large vessel occlusions, respond poorly to current therapies. Resistance to clot-busting drugs and bleeding risks limit treatment options. Research is ongoing to develop safer drugs, improve mechanical interventions, and find therapies that protect brain cells from damage. Addressing these gaps remains a priority to improve outcomes for all stroke patients.
Why Clinical Trials Matter for Stroke
Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial often means closer medical monitoring and support throughout the study period. Patients can contribute to advancing medical knowledge that may help others in the future. According to ClinicalTrials.gov, there are currently 532 stroke clinical trials indexed, with 236 actively recruiting participants. This shows a strong ongoing effort to find better therapies and improve care standards.
Joining a clinical trial also involves some risks. The effectiveness of new treatments is not guaranteed, and some participants may receive a placebo instead of the active drug. Additional visits to clinics or hospitals may be required for monitoring and tests. Side effects from experimental treatments can occur and may be unknown at the start of the trial. Patients should carefully weigh these factors and discuss them with their healthcare providers before enrolling.
The sponsors of stroke clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in funding and conducting studies to explore new drugs, devices, or treatment approaches. ClinicalTrials.gov serves as a central registry where patients and caregivers can find detailed information about ongoing and upcoming trials. This resource helps connect interested individuals with research opportunities that match their condition and needs.
What to Look for in a Stroke Clinical Trial
Clinical trials are conducted in phases 1 through 4, each with a specific purpose. Phase 1 trials test safety and dosage in a small group of participants. Phase 2 trials focus on effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to the current standard in an even larger group. Phase 4 trials happen after approval to monitor long-term effects. For stroke trials, many studies do not specify a phase (343 out of 532). The most common specified phase is Phase 3, with 31 trials, followed by Phase 2 with 29, and Phase 4 with 14. This shows many trials focus on testing treatments against current options or monitoring safety after approval.
Inclusion criteria for stroke clinical trials often depend on factors like age, previous treatments, and the stage of stroke recovery. Age ranges usually include adults from 18 years and older, but some trials may focus on older adults or specific age groups. Participants might need to have had a recent stroke or be within a certain time frame since their stroke occurred. Some trials require specific biomarkers or imaging results to confirm the type and severity of stroke. Others look at disease duration, such as acute stroke within hours or months after the event. These criteria help researchers study the treatment in a group most likely to benefit.
Exclusion criteria are equally important and are designed to keep participants safe and ensure reliable results. People with other serious health conditions, like severe heart disease or uncontrolled diabetes, may be excluded. Some trials avoid participants taking certain medications that could interact with the study treatment. Safety thresholds might exclude those with abnormal lab results or unstable vital signs. These rules protect participants from harm and prevent other health issues from affecting the study’s findings. Understanding these criteria can help patients and caregivers determine if a trial is a good fit.
Practical considerations matter a lot when joining a stroke clinical trial. The length of the trial can vary from a few weeks to several months or longer. Visit schedules might include frequent check-ups, tests, or therapy sessions. Travel to the study site may be required, which can be challenging for some patients. Before joining, it is helpful to ask the research team four key questions: What are the potential risks and benefits? How often will I need to visit the site? Will travel or accommodations be reimbursed? What happens if I decide to leave the study early? These questions help patients and caregivers prepare for the experience and make informed decisions.
Primary Sources and Further Reading
For those interested in learning more about stroke and clinical trials, it is important to consult reliable and authoritative sources. These websites offer detailed information on stroke symptoms, treatments, ongoing research, and how to participate in clinical studies. They are maintained by government health agencies and research institutions. Below are some trusted links to help you explore further.
- MedlinePlus Stroke Information
- National Institute of Neurological Disorders and Stroke (NINDS) Stroke Info
- ClinicalTrials.gov Stroke Studies
- Centers for Disease Control and Prevention Stroke Resources
Latest Research and Emerging Treatments for Stroke (2026)
Recent stroke research is focusing on new drugs and therapies that could improve recovery and reduce the risk of future strokes. One promising area involves milvexian, an oral medication being tested in a large international trial (NCT05702034). Milvexian works by targeting blood clotting factors to lower the chances of another ischemic stroke or transient ischemic attack. If this drug proves safer or more effective than current options, it could offer patients a new way to prevent repeat strokes with a simple pill.
Another group of studies is exploring the use of tenecteplase, a clot-busting drug, in different settings of acute ischemic stroke. Tenecteplase helps dissolve blood clots that block arteries in the brain, restoring blood flow. Trials are testing tenecteplase given within 24 to 72 hours after stroke symptoms begin (NCT06954155), as well as directly into arteries for medium vessel blockages (NCT07469293). These studies aim to expand stroke treatment options beyond the early hours when current therapies are most effective. For patients, this could mean more chances for recovery even if they arrive late to the hospital.
Additional research compares tenecteplase with alteplase, another clot-busting drug, combined with mechanical thrombectomy for large vessel occlusion strokes (NCT06658197). Mechanical thrombectomy physically removes clots, and adding drugs like tenecteplase might improve outcomes. There is also a trial testing tenecteplase in patients treated 4.5 to 9 hours after symptoms start (NCT07540416), potentially helping those who miss the usual treatment window. These new drugs for stroke could lead to more personalized and effective stroke treatment in 2026 and beyond, providing hope for better recovery and fewer disabilities.
Frequently asked questions about Stroke trials
How do I find Stroke clinical trials?
The authoritative source for Stroke clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 532 stroke studies are currently indexed. You can search by entering "stroke" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new stroke trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Stroke trials in?
Across the 532 stroke trials TrialsAlert indexes, the most common phase is Phase 3. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Stroke clinical trials are currently recruiting?
As of the latest scan, 236 stroke trials have a "Recruiting" status on ClinicalTrials.gov, out of 532 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting stroke trial matches their tracked condition.
Stay informed about stroke research
Get a weekly briefing with the trials that matter most.